88650-17-3

88650-17-3 structure

Name: FX-06
Chemical Name: FX-06
CAS Number: 88650-17-3
Molecular Formula: C₁₃₃H₂₁₆N₄₄O₃₈
Molecular Weight: 3039.41
Catalog: Research Areas Cardiovascular Disease
Create Date: 2022-11-21 20:46:22
Modify Date: 2025-08-26 13:05:23
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS)[1][2][4].

Name	FX-06

Description	FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS)[1][2][4].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
In Vitro	FX-06 (50 μM, 3 days) inhibits the production of D2HG in HEK-293T cells transfected with IDH1 R132H[2].
In Vivo	FX06 (2.4 mg/kg, i.v. bolus) shows significantly improved pulmonary and circulatory function in a pig model of hemorrhagic shock and reperfusion[3]. FX06 (2.4 mg/kg, i.p., twice daily) improves survival and reduces capillary leak in mice with Dengue-induced shock[4]. FX06 (3.6 mg/kg, i.v.) protects mice from Ischemia/reperfusion (I/R)-induced kidney injury by aiding in epithelial cell proliferation and tissue repair[5]. Animal Model: Pig model of hemorrhagic shock and reperfusion [3] Dosage: 2.4 mg/kg Administration: Intravenous injection (i.v.) bolus Result: Reduced raccumulation of myeloperoxidase-pos. cells (mainly neutrophils) in myocardium, liver, and small intestine, and reduced interleukin-6 plasma levels. Animal Model: Mice with Dengue-induced shock[4] Dosage: 2.4 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Significantly improved survival rates, reduced capillary leak within lungs and the intestine, and reduced hemoconcentration and fibrinogen consumption.
References	[1]. Ahrens I, et al. FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003. [2]. Zou F, et al. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorg Med Chem Lett. 2018 Feb 1;28(3):388-393. [3]. Roesner JP, et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med. 2009 Feb;37(2):598-605. [4]. Gröger M, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One. 2009;4(4):e5391. [5]. Aparna Krishnamoorthy, et al. Fibrinogen β–derived Bβ15-42 peptide protects against kidney ischemia/ reperfusion injury. Blood (2011) 118 (7): 1934–1942.

Molecular Formula	C₁₃₃H₂₁₆N₄₄O₃₈
Molecular Weight	3039.41

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

88650-17-3	1426138-42-2
213971-34-7	1184301-42-5
2172617-15-9	729-46-4
610279-06-6	1808266-58-1
2556836-50-9	392723-06-7
1421498-83-0	1421516-17-7
1421505-33-0	1421498-92-1
1421492-23-0	1421456-30-5
1421465-17-9	1421495-06-8
1421516-26-8	1243472-11-8